Royalty-Stream Acquisition Finance Leader

The mandate

An investment platform acquired interests in twelve marketed and late-stage therapy royalty streams from several sellers. The first post-close cycle revealed cash receipts without product or territory detail, milestone notices arriving after valuation dates, payer and distributor deductions not contemplated in models, and waterfall calculations maintained in seller spreadsheets. No single team can demonstrate contractual entitlement from reported sales through bank receipt.

The interim will assume Kuala Lumpur authority within three weeks and lead for sixteen months through four reporting quarters, two valuation rounds and a full audit. A permanent head of royalty finance will be recruited once every stream has a validated entitlement map and two consecutive quarters reconcile within tolerance, forecast for month nine. Seven weeks of overlap will include one close and one licensor challenge led by the successor.

Transfer readiness means each asset has an executed-rights abstract, product and territory hierarchy, sales-source map, milestone calendar, deduction taxonomy, tiered-rate engine, currency and tax treatment, cash-waterfall control, valuation linkage and named owner. The incoming leader must receive exception histories, audit evidence, disputed amounts, data-access constraints, counterparty contacts and a calendar of clinical or commercial triggers.

Within approved policy, the interim may suspend recognition unsupported by contract, hold distributions, demand administrator recalculation, redirect finance analysts and authorise up to MYR 40 million for data, control and specialist remediation. Amendments to royalty agreements, litigation, clinical judgments, investment valuation conclusions, tax elections and settlements above delegated limits remain with the appropriate committee or officers.

Drug-development strategy, prescribing forecasts, medical assessment, new investment origination and portfolio-company operations are excluded. This seat controls contractual-to-cash evidence, reporting, waterfall operation, counterparty exceptions, auditability and permanent-team installation for the acquired streams. It must preserve uncertainty explicitly instead of translating missing territory data or disputed deductions into convenient revenue assumptions.

Why this seat is open

Closing transferred economic rights faster than the supporting data, administration and financial controls could be rebuilt. Investment teams understand the thesis, while licensors control much of the reporting detail and legal teams interpret the contracts. Temporary royalty-finance authority is needed to create a repeatable entitlement-to-cash system through actual milestone, payment, valuation and audit cycles.

What you will own

• Convert every royalty contract into controlled product, indication, territory, rate tier, milestone, deduction, currency and payment attributes.
• Reconcile partner-reported sales through allowed adjustments, withholding, administrator calculations, invoices, receivables, collections and beneficiary distributions.
• Establish evidence requirements for regulatory, clinical, sales and cumulative-threshold milestones, including notice dates and subsequent confirmation.
• Investigate distributor fees, government rebates, returns, gross-to-net effects and territorial leakage against each agreement’s economic language.
• Connect realised royalty behaviour and contractual exceptions to valuation inputs without directing clinical forecasts or approving fair value.
• Run four quarterly closes, two valuation support cycles and an external audit with versioned calculations and signed exception treatment.
• Hand the successor asset dossiers, automated waterfall controls, dispute files, counterparty calendars and a trained royalty-accounting team.

Candidate qualifications

• Held senior finance control over acquired pharmaceutical royalties, licensing income, intellectual-property revenues or similarly contingent contractual cash flows.
• Translated complex rate tiers, territory rights, milestones and allowable deductions into reproducible calculations and accounting evidence.
• Reconciled licensor statements, administrator waterfalls, withholding taxes, foreign exchange and bank cash across multiple beneficiaries.
• Challenged gross-to-net deductions and reporting gaps using contract-specific evidence without making unauthorised legal or clinical determinations.
• Supported fair-value and audit processes by connecting actual asset behaviour to model assumptions and documented uncertainty.
• Built a permanent control function that survived reporting, valuation, dispute and external-audit cycles after an acquisition.

Non-negotiables

• Can take onsite Kuala Lumpur responsibility within three weeks and travel quarterly to licensors and administrators.
• Will accept exclusive executive accountability for reporting and cash control across the twelve acquired streams.
• Brings direct contingent-rights or biopharma royalty finance depth; ordinary licence accounting alone does not qualify.
• Must disclose relationships with sellers, licensors, administrators, portfolio companies, valuation firms and audit providers.

1. 49 words maximum. Describe a royalty cash shortfall you traced to a contractual deduction or territory-reporting failure.
2. 49 words maximum. What evidence would you require before recognising a development or commercial milestone receivable?
3. 49 words maximum. State your Kuala Lumpur availability and the largest contingent-rights portfolio you controlled.